Invention Grant
- Patent Title: Peptide for suppressing osteoclast differentiation and use thereof
-
Application No.: US15875669Application Date: 2018-01-19
-
Publication No.: US10669312B2Publication Date: 2020-06-02
- Inventor: Yong-Ji Chung , Eun-Mi Kim , Eung-Ji Lee , Tae-Hoon Lee , A-Reum Han
- Applicant: CAREGEN CO., LTD.
- Applicant Address: KR Anyang-si
- Assignee: CAREGEN CO., LTD.
- Current Assignee: CAREGEN CO., LTD.
- Current Assignee Address: KR Anyang-si
- Agency: Clark & Elbing LLP
- Agent Susan M. Michaud
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@6dcf8fbc
- Main IPC: C07K7/08
- IPC: C07K7/08 ; C07K14/54 ; A61K38/00

Abstract:
The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (IL)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of NF-κB and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL)-RANK signaling pathway, and suppresses the expression of a RANKL or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (TRAP), cathepsin K, or TNF receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration. Moreover, the peptide of the present invention can contribute to osteoblast differentiation by promoting the expression of osteoblast differentiation markers such as osteocalcin (OCN), osteoprotegerin (OPG), bone sialoprotein (BSP), or osteopontin (OPN). Therefore, the superior activity and stability of the peptide of the present invention are useful for medicines, sanitary aids, or cosmetics.
Public/Granted literature
- US20180170966A1 PEPTIDE FOR SUPPRESSING OSTEOCLAST DIFFERENTIATION AND USE THEREOF Public/Granted day:2018-06-21
Information query